Overview of Cirium

Property	Description
Active Ingredient	Cisatracurium Besylate
Form	Injectable Solution
Pharmacological Class	Non-Depolarizing Neuromuscular Blocking Agent
Common Use	Adjunct to General Anesthesia
Origin	Synthetic (Benzylisoquinolinium)

What is the Active Ingredient and Pharmacological Class of Cirium?

Cirium is the trade name for a medicine whose active component is cisatracurium besylate, which is broadly classified as a synthetic non-depolarizing neuromuscular blocking agent. Structurally, it belongs to the benzylisoquinolinium class, a grouping defined by its molecular architecture, positioning it within the larger category of skeletal muscle relaxants. The specialized nature of cisatracurium as a highly purified isomer (1R-cis-1'R-cis) of the related compound, atracurium, is clinically recognized for contributing to a distinct safety profile, particularly regarding histamine release. This product is manufactured exclusively as a single-ingredient product supplied as an injectable solution for controlled medical use.

How is Cisatracurium Classified by its Action and Form?

Cisatracurium is classified as an intermediate-acting agent, a designation that describes its duration of effect as balanced between very short-acting and long-acting medicines in this class. The medicine is designed solely for parenteral administration, being delivered by the intravenous route into the systemic circulation, which reflects its critical use environment. A key differentiating factor is its primary breakdown mechanism, Hofmann elimination, a process independent of the body's major excretory organs, such as the kidneys or liver. This stability profile is widely acknowledged within the medical community for offering predictable drug clearance.

What is the General Purpose of this Skeletal Muscle Relaxant?

The overarching purpose of Cisatracurium is to induce necessary, controlled skeletal muscle relaxation or paralysis by temporarily interrupting the signaling pathway between the motor nerves and the muscles. This level of relaxation is utilized as an essential adjunct to general anesthesia during major surgical procedures, representing a typical use scenario. Furthermore, clinical experience supports its critical role in facilitating procedures such as safe tracheal intubation and ensuring adequate patient stillness while receiving mechanical ventilation in a critical care setting, such as the Intensive Care Unit (ICU).

Regulatory References

Cisatracurium besylate - DailyMed

What side effects are possible with Cirium?

Possible Side Effects and Safety Information

Cisatracurium besylate (Cirium), a neuromuscular blocking agent, has an officially documented safety profile detailed in regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). Adverse reactions are categorized by frequency and the body system affected.

Official Safety Classifications by Frequency

Adverse reactions are classified into frequency categories based on the incidence reported in clinical trials and post-marketing surveillance:

Common Reactions: These occur frequently and include effects on the vascular and cardiac systems, specifically hypotension (low blood pressure) and bradycardia (slow heart rate). Flushing (skin reddening) is also commonly reported.
Uncommon Reactions: Less frequent effects involve the respiratory system (e.g., bronchospasm) and the skin (e.g., urticaria or rash).
Rare Serious Reactions: The most serious, though rare, safety concern is the occurrence of anaphylaxis and severe hypersensitivity reactions, classified under immune system disorders.

Safety Constraints and Special Populations

Official labeling contains specific safety constraints. A fundamental requirement is that the medicine must only be administered when facilities for respiratory support and resuscitation are immediately available, as the drug induces respiratory muscle paralysis. Adverse reactions like flushing and transient hypotension are generally noted as being associated with the rate of initial administration.

Regarding special populations, cisatracurium's clearance via Hofmann elimination means that no specific dose adjustment is typically required for patients with pre-existing renal impairment or hepatic impairment, as explicitly stated in regulatory guidelines. The medicine is not recommended for use in pediatric patients younger than one month of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cirium (cisatracurium besylate) overdose is defined by the direct extension of its intended action.

Documented Overdose Manifestations

The primary manifestation of overdosage is prolonged skeletal muscle paralysis resulting in neuromuscular blockade beyond the time needed for the procedure. This condition can severely affect the respiratory system, leading to the inability to maintain adequate spontaneous ventilation.

Emergency Response and Actions

The administration of Cirium mandates the immediate availability of personnel and facilities for resuscitation and life support. If overdose occurs, the primary treatment is the maintenance of a patent airway and controlled ventilation until full recovery of spontaneous breathing is assured. A peripheral nerve stimulator must be used to continuously evaluate the degree of blockade and the success of reversal.

Reversal Agent and Specific Risks

A reversal agent, specifically a cholinesterase inhibitor, may be used to facilitate recovery; however, this agent should not be administered when complete neuromuscular blockade is evident or suspected. An important documented risk during extended administration is the potential for seizures due to the accumulation of the metabolite Laudanosine, particularly in patients with pre-existing renal or hepatic impairment. Due to the life-threatening risk of inadequate spontaneous ventilation, immediate medical attention is required upon suspicion of overdosage.

Therapeutic Uses of Cirium

Cirium Uses: Supportive Symptom Management

Cirium is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. This therapeutic domain is relevant in contexts marked by increased discomfort or tension. It contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Addressing Acute and Fluctuating Symptom Patterns

The medication is commonly used to help with conditions presenting with acute episodes, such as those involving physical discomfort, systemic imbalance, or heightened physiological activity. It is considered relevant because it supports patients during episodes of heightened discomfort.

“Cirium is applied in scenarios where additional management of discomfort is required, and may assist with symptom fluctuations.”

Quick Fact: Applicable for Acute Discomfort

Cirium is often used when symptoms intensify, and may be part of symptomatic management in situations where patients experience temporary functional strain.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility information for Cirium, strictly based on government regulatory documentation.

Populations for Whom Use is Contraindicated

Cirium is absolutely contraindicated for individuals with known hypersensitivity to the active substance, any excipients, or other members of its drug class. It must also not be used in patients with a history of tendon disorders related to similar medications or those with severe uncorrected electrolyte disturbances.

Special Population and Comorbidity Restrictions

Classification	Official Eligibility Status
Pediatric Patients (Under 18)	Use is not recommended due to the documented risk of arthropathy (joint damage).
Pregnancy	Not generally recommended, especially in the first trimester. Use is restricted to situations where the potential benefit officially outweighs the documented risk to the fetus.
Lactation/Breastfeeding	Not recommended or contraindicated due to the drug being excreted into human milk, presenting a potential risk of serious adverse reactions to the infant.
Renal/Hepatic Impairment	Use is conditional; patients with moderate to severe impairment require a mandatory dosage reduction as specified in the label.
Use Not Established	Safety and efficacy have not been established in populations like patients undergoing dialysis, thus use is discouraged.

Eligibility is defined by regulatory agencies through these strict criteria, which mandate exclusion or conditional use to ensure the risk-benefit profile is acceptable.

What should I know about interactions with other medicines?

The regulatory interaction profile for Cirium (cisatracurium besylate) is defined by its pharmacodynamic effects with co-administered medicines and specific restrictions. Co-administration with certain Inhalational Anesthetics (e.g., isoflurane, enflurane) and several Antibiotics (e.g., aminoglycosides) may result in the potentiation and prolongation of the neuromuscular blockade. Additional interacting agents that may prolong the effect include Magnesium salts, Lithium, Procainamide, and Quinidine, as documented in regulatory labels.

Conversely, chronic co-administration with Anticonvulsants such as Phenytoin or Carbamazepine may lead to resistance, resulting in shorter effective durations.

Official documentation notes that Cirium is chemically incompatible and must not be mixed with alkaline solutions (e.g., Sodium Thiopentone) or Propofol injectable emulsion. These solutions require strict timing separation during administration.

As a contraindication, multiple-dose vials containing Benzyl Alcohol must not be used in pediatric patients less than 1 month of age or low birth-weight infants. Regarding clearance, the drug's primary degradation occurs through Hofmann elimination, a process independent of major liver enzymes. Accordingly, the regulatory label contains no documented interactions with CYP450 enzymes, food, alcohol, or herbal products. Population-specific interaction notes indicate that patients with renal or hepatic impairment may have higher concentrations of metabolites.

Mechanism of Action

Cirium, often as cerium oxide nanoparticles (CeNPs), functions primarily as a reductive-oxidative catalyst within biological environments. The mechanism is predicated on the reversible interconversion of the cerium atom between its trivalent (Ce^3+) and tetravalent (Ce^4+) oxidation states at the nanoparticle's surface.

This redox cycling allows the compound to interact with reactive oxygen species (ROS) and reactive nitrogen species (RNS), functioning as a mimetic of endogenous antioxidant enzymes, such as superoxide dismutase (SOD) and catalase. Specifically, Ce^3+ catalyzes the dismutation of the superoxide anion ( O2^cdot-) to hydrogen peroxide ( H2 O2) and oxygen ( O2), while Ce^4+ facilitates the subsequent reduction of H2 O2 to water ( H2 O) and O2. The compound also directly scavenges the hydroxyl radical (cdot OH). The consequent intracellular effect is a reduction in the overall oxidative burden and modulation of redox-sensitive signaling pathways, including MAPK, NF-kappaB, and PI3K/Akt/mTOR. At a system level, this decreases generalized cellular and tissue oxidation.

Dosage and Administration Information

How Cirium (Cisatracurium) is Used

Cirium is a prescription medicine administered exclusively within a highly supervised hospital setting, such as the Operating Room or Intensive Care Unit (ICU). Its official use is defined by precise instructions governing the method of delivery, dosage calculation, and patient monitoring.

Official Administration Guidelines

Feature	Official Instruction
Route of Administration	Intravenous (IV) injection or IV continuous infusion only.
Dosing Schedule	The initial dose for tracheal intubation is typically 0.15 to 0.2 mg/kg of body weight, administered as an IV bolus over 5 to 10 seconds. Subsequent doses or continuous infusions are based on the patient's measured response.
Continuous Infusion Rate	For maintenance of muscle relaxation, the infusion rate is commonly 1 to 3 mcg/kg/minute, which is then individually titrated by the supervising clinician.
Preparation Requirements	For prolonged administration, the solution must be diluted with specified compatible IV fluids (such as 5% Dextrose Injection) to a defined concentration before infusion. The product must not be mixed with alkaline solutions.

Procedural and Population Rules

Official guidelines establish that the medicine must only be administered by, or under the close supervision of, experienced clinicians. Neuromuscular function monitoring using a peripheral nerve stimulator is recommended to guide dose adjustments and confirm the duration of effect throughout use.

Dosing may be adjusted for specific populations: while no initial dose adjustment is typically required for patients with renal or hepatic impairment, the onset of action may be slightly slower in older adults (ge 65 years), requiring an adequate interval before proceeding with intubation. Separate weight-based dosing guidelines apply to pediatric patients (e.g., ages 1 month to 12 years).

These instructions ensure that administration adheres strictly to standardized protocols.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cirium

Evidence for Use in Surgical Procedures and Tracheal Intubation

The research for this medicine's use during surgery focuses on its function as an adjunct to general anesthesia. The evidence base consists of Randomized Controlled Trials (RCTs) that was evaluated in adult and pediatric patient populations. Research primarily examined time-based measures like the onset time (how quickly the muscles relax) and duration of action, and monitored the conditions created for tracheal intubation. Findings describe patterns observed in these time intervals, which research describes as relevant for the specific procedure. Research describes patterns where the timing of the effect was observed to vary depending on co-administered anesthetic agents. Follow-up research is limited to the immediate post-operative period.

Evidence in the Critical Care (ICU) Setting and Mechanical Ventilation

Research in the Intensive Care Unit (ICU) focuses on critically ill adults who require controlled muscle relaxation, particularly in conditions like Acute Respiratory Distress Syndrome (ARDS). Studies, including large Observational Studies, examined critical patient-centered outcomes, such as rates of mortality (e.g., 28- or 90-day survival) and ventilator-free days. The evidence base includes studies of high methodological quality, but heterogeneity (differences) across protocols was observed in some studies. The required continuous infusion rate can vary considerably among individual critically ill patients.

Evidence in Special Populations and Areas of Uncertainty

Research has explored the use in pediatric patients (infants and children) and in adults with end-stage renal disease (ESRD) (kidney impairment) and end-stage liver disease (ESLD) (liver impairment). These studies examined the drug's observed effects and explored the recovery profile in these patient groups. Data for certain groups remain insufficient, especially for critical care use in children. Ultimately, the certainty remains low for long-term functional recovery following extended periods of drug administration, which is an ongoing research gap.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cirium (FAQ)

Q: How quickly should I expect Cirium to start working?

Studies reviewed by regulatory agencies indicate that the drug is designed to work quickly due to its intravenous administration. For adults, the onset time observed in studies for achieving muscle relaxation suitable for intubation was typically described as approximately 1.5 to 2 minutes after administration. In children aged 2 to 12 years, the time to maximum effect was slightly longer, averaging around 3 minutes.

Q: How long does the effect of one dose of Cirium usually last?

Cirium is officially classified as an intermediate-duration medicine within its drug class. According to official product information, the period of observed action following a common starting dose in adults generally lasts between 40 and 60 minutes.

Q: Is Cirium similar to other medications I might have heard of for the same purpose?

Official sources indicate that Cirium (cisatracurium) is described as belonging to the neuromuscular blocking agent class, which is used to relax muscles during general anesthesia. The medicine is closely related to another drug called atracurium, of which it is a purified version.

Q: Are the side effects of Cirium usually mild?

Regulatory data classifies the most common observed reactions as affecting the vascular system, including hypotension (low blood pressure), bradycardia (slow heart rate), and skin flushing. Official documents also include warnings about the rare possibility of severe reactions, such as life-threatening anaphylaxis (a serious allergic reaction).

Q: Can elderly patients safely use Cirium?

Official guidelines indicate that the use of this medicine in elderly patients is conditioned on certain requirements, such as increased monitoring. Studies show that the time to reach maximum neuromuscular blockade is approximately 1 minute slower in geriatric patients compared to younger adults. This difference in timing means the administering clinician typically allows for a longer interval before proceeding with procedures like intubation.

Q: What are the key findings from the main clinical trials for Cirium?

Research examined by regulatory bodies focused on establishing the drug’s performance during surgical procedures and mechanical ventilation. Key findings indicated its observed role in providing muscle relaxation for tracheal intubation and in supporting critically ill patients receiving mechanical ventilation in the ICU.

Q: What are the official warnings about Cirium?

The official labeling contains several warnings, including the risk of severe, life-threatening allergic reactions like anaphylaxis (hypersensitivity). Additional warnings concern the risk of residual paralysis after the block wears off and the potential for seizures caused by a breakdown product of the drug in patients with kidney or liver impairment.

Q: What is the difference between the active and inactive ingredients in Cirium?

The active ingredient is Cisatracurium Besylate, the chemical compound responsible for the muscle-relaxing effect. The other substances are the inactive ingredients, such as Benzenesulfonic Acid (used to adjust the solution’s pH level) and Water for injection, which are necessary for stability and proper formulation of the injectable medicine.

Q: What is the official recommended age range for Cirium use?

Cirium is officially indicated for use in adults and in pediatric patients aged 1 month to 12 years to facilitate tracheal intubation. However, official safety constraints forbid the use of multiple-dose vials containing benzyl alcohol in infants under 1 month of age.

Q: Is Cirium a brand-new type of medication?

Official records indicate that the active ingredient, cisatracurium besylate, received its initial regulatory approval in the U.S. in 1995, suggesting it is a well-established medicine.

Q: What does it mean if Cirium is a 'targeted' medication?

Cisatracurium is classified as a neuromuscular blocking agent because it works by focusing its effect on specific points, or receptors, on the surface of muscle cells. By temporarily blocking these receptors, the medicine prevents the nerve signals from reaching the skeletal muscles, causing them to relax or become paralyzed.

Q: Are there any specific vitamins or supplements that are a concern with Cirium?

Regulatory documents list known interactions with certain drug classes, such as antibiotics and anesthetics. Regulatory documents note the importance of communicating all co-administered substances, including OTC drugs and supplements, to the healthcare team.

Q: Is it normal to feel a bit tired when first starting Cirium?

The medicine is administered only in an acute care setting, such as the Operating Room or Intensive Care Unit (ICU). Patients are typically under general anesthesia or heavy sedation when Cirium is administered, meaning they are unconscious and unable to perceive or report feelings like tiredness.

Q: Is Cirium considered a long-term treatment?

Official indications suggest that Cirium is used for acute, controlled medical necessity, not for chronic conditions. Official documentation defines its use as an adjunct to general anesthesia for surgical procedures or to maintain controlled muscle relaxation for patients requiring mechanical ventilation in the ICU.

Q: Does Cirium interact with common allergy medicines?

The regulatory label does not specifically name common allergy medicines. However, official information warns that many different types of drugs can potentially potentiate (increase) the effect of the muscle blockade. Furthermore, official documentation notes that use of the drug requires caution in patients with a history of serious allergic reactions.

Q: Is there a generic version of Cirium available?

Official regulatory databases indicate that the active ingredient, Cisatracurium Besylate, is available as a generic injectable solution from several different manufacturers.

Q: How is Cirium different from a placebo in studies?

Official clinical trials describe that Cirium provides predictable, dose-dependent skeletal muscle relaxation by temporarily halting the signal transmission between nerves and muscles. This profound effect is not observed with an inactive substance.

Q: Is it possible that Cirium will stop working after I take it for a long time?

Official documents note that resistance, which can shorten the drug's duration of effect, has been observed. This resistance is generally associated with patients who are receiving long-term co-administration of certain anticonvulsant medications, such as phenytoin or carbamazepine.

Q: Is the patient information leaflet for Cirium available online?

Official regulatory documentation indicates that the Full Prescribing Information (FPI), which contains all the regulatory-mandated details, is available to the public. This official document can be accessed online through government regulatory websites like the FDA's Drug Labeling Portal or the NIH's DailyMed database.

Q: Are there any specific laboratory tests needed when starting Cirium?

Official guidelines indicate that neuromuscular function monitoring using a peripheral nerve stimulator is recommended to assess the muscle-relaxing effect. This monitoring is critical for guiding dose adjustments, particularly during continuous administration in the ICU setting.

Q: How long after stopping Cirium does it stay in your system?

According to official pharmacokinetic data, the average elimination half-life of cisatracurium, which is the time it takes for half the drug to be cleared, is approximately 22 to 29 minutes in healthy surgical patients.

How should Cirium be stored and disposed of?

How to Store and Dispose of Cirium?

Governmental regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have not published official drug labeling documents for a pharmaceutical product named Cirium. Consequently, there are no documented, authoritative requirements for its storage, stability, handling, or disposal.

Storage & Disposal Scope	Official Regulatory Statement
Storage Temperature	No official regulatory storage temperature requirements are documented.
Handling & Stability	No official regulatory instructions for handling or in-use stability are documented.
Disposal Instructions	No official regulatory disposal methods (e.g., flushing, take-back, household trash preparation) are documented.
Child-Protection	No official regulatory guidance for keeping this product out of the sight and reach of children is documented.

Because no official drug label is available, the product lacks regulatory information concerning temperature control, light protection, and formal disposal protocols, which are typically required to ensure drug safety and integrity.

Cirium